Ensem Therapeutics Doses First Patient in China in ETX-636 Global Phase 1/2 Study - Business Wire

2026-02-02 - 13:15

Ensem Therapeutics Doses First Patient in China in ETX-636 Global Phase 1/2 Study Business Wire